A systematic review of allometric scaling exponents for IgG mAbs

被引：0

作者：

Rowland, Simon Peter ^{[1
]}

Nixon, Emma ^{[2
]}

Mohan, Krithika ^{[3
]}

Wang, Qianwen ^{[4
]}

Yates, James W. T. ^{[2
]}

机构：

[1] Haleon, Bldg 5,First Floor, Weybridge KT13 0NY, Surrey, England

[2] GSK, DMPK Modelling, Stevenage, England

[3] DMPK Modelling, 1000 Winter St, Waltham, MA USA

[4] GSK, CPMS Infect Dis & Vaccine, London, England

来源：

XENOBIOTICA | 2024年 / 54卷 / 09期

关键词：

pharmacokinetics; allometric scaling; modelling mAb PK; cynomolgus monkey; mAb global scaling exponents; THERAPEUTIC MONOCLONAL-ANTIBODIES; HUMAN PHARMACOKINETICS; PREDICTION;

D O I：

10.1080/00498254.2024.2383925

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Increasing complexity of mAbs in development creates challenges in predicting human pharmacokinetic (PK) parameters from preclinical data. The aim of this analysis was to identify optimal allometric scaling exponents.Data were extracted from literature to create a central database (currently the largest available published database) of two-compartment model parameters for mAbs (n = 59) in cynomolgus monkey (CM) and human.Global allometric exponents were calculated and drug-dependent factors were investigated as potential variables in determining the optimal scaling factor.The global exponents for scaling CM mAb PK data were 0.74 (CL), 0.80 (CL with Fc-modified mAbs excluded), 0.44 (CL with Fc-modified mAbs only), 0.71 (Q), 1.12 (V1), and 0.99 (V2). These values are in line with previously published literature values.

引用

页码：609 / 614

页数：6

共 50 条

[31] Allometric scaling of marbofloxacin pharmacokinetics: a retrospective analysis
Yohannes, S.
Hossain, Md Akil
Kim, J. Y.
Lee, S. J.
Kwak, D. M.
Suh, J. W.
Park, S. C.
POLISH JOURNAL OF VETERINARY SCIENCES, 2014, 17 (01): : 99 - 103
[32] Allometric scaling of pegylated liposomal anticancer drugs
Caron, Whitney P.
Clewell, Harvey
Dedrick, Robert
Ramanathan, Ramesh K.
Davis, Whitney L.
Yu, Ning
Tonda, Margaret
Schellens, Jan H.
Beijnen, Jos H.
Zamboni, William C.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2011, 38 (05) : 653 - 669
[33] The Authors' Reply: Obesity and Allometric Scaling of Pharmacokinetics
Diepstraten, Jeroen
Knibbe, Catherijne A. J.
CLINICAL PHARMACOKINETICS, 2011, 50 (11) : 755 - 756
[34] A novel in vitro allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry
Crouch, Rachel D.
Hutzler, J. Matthew
Daniels, J. Scott
XENOBIOTICA, 2018, 48 (03) : 219 - 231
[35] Allometric scaling of kidney function in green iguanas
Maxwell, LK
Jacobson, ER
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE PHYSIOLOGY, 2004, 138 (03): : 383 - 390
[36] Allometric scaling of hepatic biotransformation in rainbow trout
Fitzsimmons, Patrick N.
Hoffman, Alex D.
Fay, Kellie A.
Nichols, John W.
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY, 2018, 214 : 52 - 60
[37] Pharmacokinetic scaling of epirubicin using allometric and species-invariant time methods
Shin D.H.
Park S.H.
Jeong S.W.
Kwon O.-S.
Park C.-W.
Han K.
Chung Y.B.
Journal of Pharmaceutical Investigation, 2015, 45 (5) : 441 - 448
[38] Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?
Calvier, Elisa A. M.
Krekels, Elke H. J.
Valitalo, Pyry A. J.
Rostami-Hodjegan, Amin
Tibboel, Dick
Danhof, Meindert
Knibbe, Catherijne A. J.
CLINICAL PHARMACOKINETICS, 2017, 56 (03) : 273 - 285
[39] Assessment of gender differences in maximal anaerobic power by ratio scaling and allometric scaling
Hazir, Tahir
Kosar, Nazan Sukran
ISOKINETICS AND EXERCISE SCIENCE, 2007, 15 (04) : 253 - 261
[40] The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults
Wang, Chenguang
Allegaert, Karel
Peeters, Mariska Y. M.
Tibboel, Dick
Danhof, Meindert
Knibbe, Catherijne A. J.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (01) : 149 - 159

← 1 2 3 4 5 →